EA201690790A1 - Серосодержащее бициклическое соединение - Google Patents
Серосодержащее бициклическое соединениеInfo
- Publication number
- EA201690790A1 EA201690790A1 EA201690790A EA201690790A EA201690790A1 EA 201690790 A1 EA201690790 A1 EA 201690790A1 EA 201690790 A EA201690790 A EA 201690790A EA 201690790 A EA201690790 A EA 201690790A EA 201690790 A1 EA201690790 A1 EA 201690790A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cognitive impairment
- schizophrenia
- cias
- charcot
- spasticity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 5
- 208000010877 cognitive disease Diseases 0.000 abstract 5
- 201000000980 schizophrenia Diseases 0.000 abstract 5
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 206010012335 Dependence Diseases 0.000 abstract 3
- 208000001640 Fibromyalgia Diseases 0.000 abstract 3
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 3
- 208000029560 autism spectrum disease Diseases 0.000 abstract 3
- 208000018198 spasticity Diseases 0.000 abstract 3
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- -1 bicyclic compound Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 abstract 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 abstract 1
- 102000005915 GABA Receptors Human genes 0.000 abstract 1
- 108010005551 GABA Receptors Proteins 0.000 abstract 1
- 210000001766 X chromosome Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Предложено соединение, полезное в качестве фармацевтической композиции для предупреждения и/или лечения шизофрении, когнитивного нарушения, связанного с шизофренией (CIAS), когнитивного нарушения, синдрома ломкой Х-хромосомы, расстройства аутистического спектра, спастичности, тревожного расстройства, наркомании, боли, фибромиалгии, болезни Шарко-Мари-Тута или тому подобного. Проведено исследование фармацевтической композиции для предупреждения и/или лечения шизофрении, когнитивного нарушения, связанного с шизофренией (CIAS), когнитивного нарушения, синдрома ломкой X-хромосомы, расстройства аутистического спектра, спастичности, тревожного расстройства, наркомании, боли, фибромиалгии, болезни Шарко-Мари-Тута или тому подобного, обладающей действием позитивного аллостерического модулятора (РАМ-действием) GABA, и установлено, что серосодержащее бициклическое соединение является РАМ рецептора GABA, и тем самым завершено данное изобретение. Серосодержащее бициклическое соединение по настоящему изобретению обладает РАМ-действием GABAи может быть полезно в качестве средства для предупреждения и/или лечения шизофрении, CIAS, когнитивного нарушения, синдрома ломкой X-хромосомы, расстройства аутического спектра, спастичности, тревожного расстройства, наркомании, боли, фибромиалгии или болезни Шарко-Мари-Тута.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013216332 | 2013-10-17 | ||
| PCT/JP2014/077653 WO2015056771A1 (ja) | 2013-10-17 | 2014-10-17 | 含硫黄二環式化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690790A1 true EA201690790A1 (ru) | 2016-08-31 |
| EA029075B1 EA029075B1 (ru) | 2018-02-28 |
Family
ID=52826697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690790A EA029075B1 (ru) | 2013-10-17 | 2014-10-17 | Серосодержащее бициклическое соединение |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9051339B2 (ru) |
| EP (1) | EP3059239B1 (ru) |
| JP (1) | JP6477484B2 (ru) |
| KR (1) | KR102248450B1 (ru) |
| CN (1) | CN105636965B (ru) |
| AR (1) | AR098070A1 (ru) |
| AU (1) | AU2014335304B2 (ru) |
| BR (1) | BR112016008654B8 (ru) |
| CA (1) | CA2927518C (ru) |
| CY (1) | CY1120880T1 (ru) |
| DK (1) | DK3059239T3 (ru) |
| EA (1) | EA029075B1 (ru) |
| ES (1) | ES2685070T3 (ru) |
| HK (1) | HK1220192A1 (ru) |
| HR (1) | HRP20181183T1 (ru) |
| HU (1) | HUE040208T2 (ru) |
| IL (1) | IL244953B (ru) |
| LT (1) | LT3059239T (ru) |
| MX (1) | MX367857B (ru) |
| MY (1) | MY177271A (ru) |
| NZ (1) | NZ719149A (ru) |
| PH (1) | PH12016500625B1 (ru) |
| PL (1) | PL3059239T3 (ru) |
| PT (1) | PT3059239T (ru) |
| RS (1) | RS57532B1 (ru) |
| SA (1) | SA516370956B1 (ru) |
| SG (1) | SG11201602926UA (ru) |
| SI (1) | SI3059239T1 (ru) |
| TW (1) | TWI648281B (ru) |
| UA (1) | UA116042C2 (ru) |
| WO (1) | WO2015056771A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| US20210346392A1 (en) | 2018-08-31 | 2021-11-11 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
| TW202220992A (zh) | 2020-08-05 | 2022-06-01 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| WO2023028519A2 (en) | 2021-08-27 | 2023-03-02 | Astellas Pharma Global Development, Inc. | Methods of treating substance use disorder |
| WO2024048714A1 (ja) * | 2022-09-01 | 2024-03-07 | アステラス製薬株式会社 | ６－（４，４－ジメチルシクロヘキシル）－４－［（１，１－ジオキソ－１λ６－チオモルホリン－４－イル）メチル］－２－メチルチエノ［２，３－ｄ］ピリミジンまたはその塩の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
| WO2002062803A1 (fr) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de thienopyrimidine |
| JP2002308882A (ja) * | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | チエノピリミジン誘導体 |
| CN1777612A (zh) * | 2003-03-31 | 2006-05-24 | 普雷迪克医药品控股公司 | 新的哌啶基氨基－噻吩并[2,3－d]嘧啶化合物 |
| JP2007509960A (ja) * | 2003-10-28 | 2007-04-19 | セプラコア インコーポレーテッド | イミダゾ［１，２−ａ］ピリジン抗不安薬 |
| GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AU2005315937A1 (en) * | 2004-12-17 | 2006-06-22 | F. Hoffmann-La Roche Ag | Thieno-pyridine derivatives as GABA-B allosteric enhancers |
| DK2041139T3 (da) | 2006-04-26 | 2012-01-16 | Genentech Inc | Farmaceutiske forbindelser |
| WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
| US8993552B2 (en) | 2009-09-04 | 2015-03-31 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
-
2014
- 2014-10-16 TW TW103135823A patent/TWI648281B/zh active
- 2014-10-17 MY MYPI2016701379A patent/MY177271A/en unknown
- 2014-10-17 LT LTEP14853825.9T patent/LT3059239T/lt unknown
- 2014-10-17 PT PT14853825T patent/PT3059239T/pt unknown
- 2014-10-17 CN CN201480057239.0A patent/CN105636965B/zh active Active
- 2014-10-17 EP EP14853825.9A patent/EP3059239B1/en active Active
- 2014-10-17 AU AU2014335304A patent/AU2014335304B2/en active Active
- 2014-10-17 AR ARP140103875A patent/AR098070A1/es active IP Right Grant
- 2014-10-17 KR KR1020167011628A patent/KR102248450B1/ko active IP Right Grant
- 2014-10-17 RS RS20180865A patent/RS57532B1/sr unknown
- 2014-10-17 DK DK14853825.9T patent/DK3059239T3/en active
- 2014-10-17 WO PCT/JP2014/077653 patent/WO2015056771A1/ja active Application Filing
- 2014-10-17 BR BR112016008654A patent/BR112016008654B8/pt active IP Right Grant
- 2014-10-17 MX MX2016004944A patent/MX367857B/es active IP Right Grant
- 2014-10-17 ES ES14853825.9T patent/ES2685070T3/es active Active
- 2014-10-17 PL PL14853825T patent/PL3059239T3/pl unknown
- 2014-10-17 JP JP2015542677A patent/JP6477484B2/ja active Active
- 2014-10-17 US US14/517,229 patent/US9051339B2/en active Active
- 2014-10-17 SI SI201430780T patent/SI3059239T1/en unknown
- 2014-10-17 NZ NZ71914914A patent/NZ719149A/en unknown
- 2014-10-17 SG SG11201602926UA patent/SG11201602926UA/en unknown
- 2014-10-17 HU HUE14853825A patent/HUE040208T2/hu unknown
- 2014-10-17 CA CA2927518A patent/CA2927518C/en active Active
- 2014-10-17 EA EA201690790A patent/EA029075B1/ru not_active IP Right Cessation
- 2014-10-17 UA UAA201605245A patent/UA116042C2/uk unknown
-
2015
- 2015-04-17 US US14/689,748 patent/US9642852B2/en active Active
-
2016
- 2016-04-06 IL IL244953A patent/IL244953B/en active IP Right Grant
- 2016-04-06 PH PH12016500625A patent/PH12016500625B1/en unknown
- 2016-04-16 SA SA516370956A patent/SA516370956B1/ar unknown
- 2016-07-14 HK HK16108264.4A patent/HK1220192A1/zh unknown
-
2018
- 2018-07-26 HR HRP20181183TT patent/HRP20181183T1/hr unknown
- 2018-08-14 CY CY20181100858T patent/CY1120880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| EA201990044A1 (ru) | Гетероциклические соединения в качестве антибактериальных средств | |
| DOP2015000289A (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
| NI201800020A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| EA201692316A1 (ru) | Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| NZ732940A (en) | Selective bace1 inhibitors | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| EA201690790A1 (ru) | Серосодержащее бициклическое соединение | |
| CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
| PH12017500920A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201691177A1 (ru) | Ингибиторы серин/треонинкиназ | |
| MY162689A (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| EA201690763A1 (ru) | Лечение рака поджелудочной железы | |
| BR112017007916A2 (pt) | compostos sarms para tratamento de distúrbios urológicos | |
| EA201891688A1 (ru) | Адамантановое производное и его применение | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| EA201790851A1 (ru) | Способы предотвращения, уменьшения и лечения макулодистрофии | |
| EA201791745A1 (ru) | Производные тетрагидропиранилбензамида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TM |